<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02222272</url>
  </required_header>
  <id_info>
    <org_study_id>EBMT-42201038</org_study_id>
    <nct_id>NCT02222272</nct_id>
  </id_info>
  <brief_title>Effect of 2nd Gen TKI in CML</brief_title>
  <official_title>Effect of Prior Therapy With Nilotinib or Dasatinib on the Outcome After Allogeneic Stem Cell Transplantation for Patients With Chronic Myeloid Leukaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Society for Blood and Marrow Transplantation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Society for Blood and Marrow Transplantation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stem cell transplantation will continue to be a treatment option for patients with chronic&#xD;
      myeloid leukaemia, despite the introduction of tyrosine kinase inhibitors. However, many&#xD;
      patients will have received prior therapy with TKIs, including Nilotinib or Dasatinib at the&#xD;
      time of allogeneic stem cell transplantation.&#xD;
&#xD;
      While the use of Imatinib prior to stem cell transplantation seems to have no adverse impact&#xD;
      on the outcome of allogeneic stem cell transplantation little is known on the impact of prior&#xD;
      use of second generation TK inhibitors.&#xD;
&#xD;
      Therefore this non interventional prospective study addresses this question and patients&#xD;
      undergoing allogeneic stem cell transplantation after prior use of 2nd generation TKIs will&#xD;
      be followed by the data office office on engraftment, treatment related mortality, relapse&#xD;
      rate and survival, prospectively. Details on TKI therapy will be collected by the&#xD;
      participating centers, retrospectively.&#xD;
&#xD;
      This is a non interventional prospective study. There is no upper limit to the number of&#xD;
      patients entered, but it is estimated that up to 450 patients will be included in 150 centres&#xD;
      for this non interventional prospective study. The registry will include patients for three&#xD;
      years plus one more year for follow up and data analysis which should then be followed-up&#xD;
      until the projected end of the non interventional prospective study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic myeloid leukemia (CML) is a clonal disorder characterized by the chromosomal&#xD;
      translocation t(9;22) which produces a fusion gene encoding the chimeric oncoprotein, BCR-&#xD;
      ABL. This protein harbors a deregulated constitutive activated tyrosine kinase (TK) leading&#xD;
      to leukemogenesis [1].&#xD;
&#xD;
      Imatinib mesylate, the first potent selective inhibitor of BCR-ABL TK [2] has become the&#xD;
      frontline therapy for newly diagnosed CML patients [3]. It can induce haematologic and&#xD;
      cytogenetic remission in all stages of CML, as well as in Ph positive acute lymphoblastic&#xD;
      leukaemia (Ph+ ALL) with minimal toxicity [4, 5]. However, resistance and relapse during&#xD;
      imatinib treatment are increasingly reported [6] and complete molecular remissions, as&#xD;
      measured by polymerase chain reaction (PCR) are rare [7-9]. Loss of response to imatinib is&#xD;
      frequently associated with mutations in the kinase domain of BCR-ABL which lead to impaired&#xD;
      imatinib binding [10-12].&#xD;
&#xD;
      Nilotinib and Dasatinib are orally available kinase inhibitors that can overcome resistance&#xD;
      to Imatinib [13 - 15]. Recent studies have demonstrated the efficacy and safety of both&#xD;
      Nilotinib and Dasatinib in all stages of imatinib resistant CML. However, the long-term&#xD;
      durability of these responses is uncertain yet, and substantial toxicity has been encountered&#xD;
      [16]. Major adverse events observed during Nilotinib therapy were cytopenias, bone marrow&#xD;
      suppression, gastrointestinal haemorrhage, diarrhea, cardiac dysfunction, liver toxicities&#xD;
      and dermatitis [17-19] and during Dasatinib therapy grade 3/4 thrombocytopenia and&#xD;
      neutropenia were reported in nearly half of the patients and non-hematologic toxicity&#xD;
      consisted primarily of diarrhea, headache, fatigue, dyspnea and pleural effusion [20, 21].&#xD;
&#xD;
      Allogeneic stem cell transplantation (SCT) is now used mainly as salvage or curative therapy&#xD;
      in patients with advanced CML who were previously treated with imatinib. While one study&#xD;
      showed higher incidence of graft versus host disease (GVHD), venoocclusive disease (VOD) and&#xD;
      transplant related mortality (TRM) [22], most studies have demonstrated that imatinib therapy&#xD;
      prior to allogeneic SCT doesn't adversely affect transplantation outcome [23,24] . By&#xD;
      contrast, previously used therapies for CML including busulfan and interferon alpha (if&#xD;
      administrated less than 3 months before allogeneic SCT) have been reported to increase&#xD;
      transplant related toxicities and mortality in CML patients undergoing allogeneic SCT [25,&#xD;
      26].&#xD;
&#xD;
      The impact of pre-transplant nilotinib or dasatinib therapy on transplant related&#xD;
      complications, morbidity and outcome is mostly unknown and only two small case series have as&#xD;
      yet been reported on this topic [27, 28]. However, allogeneic SCT will continue to be used as&#xD;
      a salvage or curative therapy for CML especially in cases with resistance to kinase&#xD;
      inhibitors or in patients at high risk of relapse, such as those in second chronic phase&#xD;
      after blast crisis [29]. In the future 2nd generation TKIs may replace at least in part&#xD;
      imatinib as frontline therapy for CML or will continue to be used in imatinib resistant&#xD;
      patients. Nevertheless, in high risk patients allogeneic transplantation appears to remain&#xD;
      the only curative treatment option.&#xD;
&#xD;
      For this reason, it is important to determine whether these novel treatments will not&#xD;
      compromise transplantation outcome and increase transplant related complications.&#xD;
&#xD;
      Research design:&#xD;
&#xD;
      This is a non interventional prospective study with regard to SCT and follow-up. Patients&#xD;
      agreeing to SCT will be identified from the EBMT database and from the transplant physicians.&#xD;
      Transplant centres for the non interventional prospective study will be chosen from the EBMT&#xD;
      centers that have transplanted patients with CML over the past 5 years. Transplant centers&#xD;
      willing to participate will be registered with the EBMT Leiden Office. A prospective registry&#xD;
      will keep record of all patients undergoing allogeneic SCT who had received prior treatment&#xD;
      with 2nd generation TKIs and a specific data collection form (MED-B / MED-C) will be sent to&#xD;
      the transplant centre to capture the relevant information at the appropriate intervals (day&#xD;
      +100; 1 year; 2 years). Data will be collected regarding the safety and feasibility of stem&#xD;
      cell transplant after Nilotinib or Dasatinib therapy (see endpoints).&#xD;
&#xD;
      The data on the treatment of patients with Nilotinib or Dasatinib before SCT will be&#xD;
      collected retrospectively as part of the medical history (retrospective data collection).&#xD;
      Participating centers planning an allogeneic SCT in a patient with CML previously treated&#xD;
      with Nilotinib or Dasatinib will register the patient with the EBMT Leiden Office prior to&#xD;
      transplant (day 0). A specific MED-C form will be sent to the centers immediately after&#xD;
      registration.&#xD;
&#xD;
      All patients transplanted in an EBMT centre give specific consent for the collection and&#xD;
      release of clinical data to the EBMT registry. Therefore, all patients registered in this non&#xD;
      interventional prospective study would have signed an informed consent to authorise the&#xD;
      release of medical information to the EBMT for the non interventional prospective study. Each&#xD;
      centre will use their own standard consent form and information sheet. No specific consent&#xD;
      form is envisaged for this non interventional prospective study.&#xD;
&#xD;
      Study Population:&#xD;
&#xD;
      This is an observational non interventional prospective study using the existing framework of&#xD;
      the EBMT to identify and include patients. In 2006 560 patients with CML received an&#xD;
      allotransplant, coming down from 800 in 2003. The percentage of patients transplanted not in&#xD;
      first chronic phase is constantly increasing. Currently no data are available how many of&#xD;
      those had previously been treated with 2nd generation TKI: it is however assumed, that also&#xD;
      the number of patients transplanted after therapy with second generation TKI is increasing.&#xD;
&#xD;
      An estimate number is that for the next three years approximately 1500 allotransplants for&#xD;
      CML will be done. 60% of these pts (n=900) would have received 2nd generation TKI. Assuming&#xD;
      that at least 50% of them will be registered in the non interventional prospective study, it&#xD;
      is expected that up to 450 patients will be identified over the next three years.&#xD;
&#xD;
      Patients response status to treatment with second line TKI (e.g. in stable CCyR, MCyR, or&#xD;
      resistant to or progressing under 2nd line TKI) will be recorded to allow for identification&#xD;
      of subgroups.&#xD;
&#xD;
      Research variables:&#xD;
&#xD;
        -  Patients' features&#xD;
&#xD;
        -  Centres' features&#xD;
&#xD;
        -  Initial diagnosis&#xD;
&#xD;
        -  Subclassification and status of disease at start 2nd generation TKI&#xD;
&#xD;
        -  Response status to treatment with 2nd generation TKI prior to SCT&#xD;
&#xD;
        -  TKI treatment (dose; duration; response)&#xD;
&#xD;
        -  Subclassification and status of disease at HSCT&#xD;
&#xD;
        -  Complications&#xD;
&#xD;
        -  Additional therapies&#xD;
&#xD;
        -  Relapse or progression&#xD;
&#xD;
        -  Last disease and patient status&#xD;
&#xD;
        -  Donor&#xD;
&#xD;
        -  Transplantation&#xD;
&#xD;
        -  Graft manipulation&#xD;
&#xD;
        -  Engraftment&#xD;
&#xD;
        -  Comorbid conditions&#xD;
&#xD;
        -  Preparative treatment&#xD;
&#xD;
        -  Graft versus Host disease&#xD;
&#xD;
        -  Follow up&#xD;
&#xD;
      Data collection:&#xD;
&#xD;
      All correspondence will go through the data centre in Leiden. The data manager from the&#xD;
      selected centre will complete the study forms. The data manager from the selected centre,&#xD;
      national registry or the Paris office will collect the data forms and will enter the MED-B&#xD;
      specific items. The MED-C items will be collected and entered by the data centre in Leiden.&#xD;
      Data analysis will be done centrally at the CLWP office.&#xD;
&#xD;
      In case of inconsistencies a second check will be performed by a research assistant/data&#xD;
      manager of the CLWP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2010</start_date>
  <completion_date type="Actual">September 29, 2017</completion_date>
  <primary_completion_date type="Actual">March 19, 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>non-relapse mortality (NRM) (treatment related mortality)</measure>
    <time_frame>1 year after HSCT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>treatment related toxic effects</measure>
    <time_frame>2 year after HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years after HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival</measure>
    <time_frame>2 years after HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Rate</measure>
    <time_frame>2 years after HSCT</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>outcome analyzed by response status to 2nd gen TKI prior to SCT</measure>
    <time_frame>2 year after HSCT</time_frame>
  </other_outcome>
  <enrollment type="Actual">432</enrollment>
  <condition>Myeloid Leukemia, Chronic</condition>
  <eligibility>
    <study_pop>
      <textblock>
        eligible patients from EBMT centres&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All adult patients with chronic myeloid leukaemia in any phase (chronic, accelerated&#xD;
             or blastic) who undergo allogeneic stem cell transplantation between 01/01/2010 and&#xD;
             30/09/2013 and have been previously treated with Nilotinib or Dasatinib, regardless of&#xD;
             their response to these drugs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Schleuning, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zentrum f√ºr Knochenmark und Blutstammzelltransplantation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduardo Olavarria, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital de Navarra, Servicio de Hematologia, Pamplona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicolaus kroeger, MD</last_name>
    <role>Study Chair</role>
    <affiliation>BMT Centre, University Hospital Eppendorf, Hamburg, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Muenster</name>
      <address>
        <city>Muenster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Ivan &amp; St Laszlo Hospital</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Centre</name>
      <address>
        <city>Tel-Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Silesia</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Petersburg State Medical Pavlov University</name>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Faisal Specialist Hospital &amp; Research Centre</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Saudi Arabia</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 19, 2014</study_first_submitted>
  <study_first_submitted_qc>August 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2014</study_first_posted>
  <last_update_submitted>August 14, 2019</last_update_submitted>
  <last_update_submitted_qc>August 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cml</keyword>
  <keyword>chronic myeloid leukemia</keyword>
  <keyword>dasatinib</keyword>
  <keyword>nilotinib</keyword>
  <keyword>tki</keyword>
  <keyword>second generation tki</keyword>
  <keyword>2nd generation tki</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

